XENE Xenon Pharmaceuticals Inc.
Q3 2025 10-Q
Xenon Pharmaceuticals Inc. (XENE) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • No newly added risk factors disclosed; risks consistent with prior 10-K
- • Most materially updated: net losses increased to $240.6M for nine months ended Sept 30, 2025, from $168.6M in same period 2024, driven by expanded R&D and G&A expenses
Quarterly Financial SummaryXBRL
Revenue
$0
Net Income
-$91M
▼ -44.8% YoY▼ -7.3% QoQ
ROE
-16.2%
Total Assets
$608M
EPS (Diluted)
$-1.15
▼ -42.0% YoY▼ -7.5% QoQ
Operating Cash Flow
-$72M
▼ -40.3% YoY▼ -11.7% QoQ
Source: XBRL data from Xenon Pharmaceuticals Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Xenon Pharmaceuticals Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.